Definium Therapeutics, Inc. (MMED.CA) Latest Company News

Sep 15, 2026, 12:45 UTC
The U.S. Food and Drug Administration held a public hearing on September 14 on how psychedelic drugs might be used as supervised treatments, with public comments open until October 5.
Source:
- medicaldaily.com
- statnews.com
Sep 14, 2026, 11:00 UTC
Definium Therapeutics reported that its LSD-based therapy DT120 eased anxiety in a second late-stage trial, with patients on a 100-microgram dose showing a 9.8-point drop on the Hamilton Anxiety Rating Scale versus a 4.7-point drop for placebo.
Source:
- statnews.com
- benzinga.com
Sep 10, 2026, 11:00 UTC
Definium Therapeutics announced six poster presentations at Psych Congress 2026, taking place September 15-19 in New Orleans, covering topline Phase 3 data from the Emerge and Voyage trials of DT120 Orally Disintegrating Tablet in major depressive disorder and generalized anxiety disorder.
Source:
- businesswire.com
Aug 17, 2026, 20:01 UTC
Definium Therapeutics issued inducement stock options to two newly hired non-executive employees to purchase an aggregate of 32,900 common shares, with effective grant dates of August 17, 2026.
Source:
- businesswire.com
Aug 12, 2026, 12:01 UTC
Definium Therapeutics announced that its LSD therapy DT120 significantly eased anxiety in a late-stage Phase 3 trial for generalized anxiety disorder.
Source:
Aug 12, 2026, 11:36 UTC
DEFINIUM THERAPEUTICS shares resumed trading and surged 24% after positive data.
Source:
- finance.sina.cn
Aug 6, 2026, 20:01 UTC
Definium Therapeutics reported its financial results for the quarter ended June 30, 2026.
Source:
- businesswire.com
Jun 24, 2026, 00:00 UTC
Definium Therapeutics, Inc. signed an underwriting agreement for an underwritten public offering of 20,588,236 common shares at $34.00 per share, with expected gross proceeds of approximately $805 million, expected to close June 25, 2026.
Source:
Jun 22, 2026, 17:23 UTC
Definium Therapeutics Inc. shares surged as much as 60% on Monday after positive late-stage trial data for its experimental depression drug.
Source:

MMED.CA

The U.S. Food and Drug Administration held a public hearing on September 14 on how psychedelic drugs might be used as supervised treatments, with public comments open until October 5.

Definium Therapeutics reported that its LSD-based therapy DT120 eased anxiety in a second late-stage trial, with patients on a 100-microgram dose showing a 9.8-point drop on the Hamilton Anxiety Rating Scale versus a 4.7-point drop for placebo.

Definium Therapeutics announced six poster presentations at Psych Congress 2026, taking place September 15-19 in New Orleans, covering topline Phase 3 data from the Emerge and Voyage trials of DT120 Orally Disintegrating Tablet in major depressive disorder and generalized anxiety disorder.

Definium Therapeutics issued inducement stock options to two newly hired non-executive employees to purchase an aggregate of 32,900 common shares, with effective grant dates of August 17, 2026.

Definium Therapeutics announced that its LSD therapy DT120 significantly eased anxiety in a late-stage Phase 3 trial for generalized anxiety disorder.

DEFINIUM THERAPEUTICS shares resumed trading and surged 24% after positive data.

Definium Therapeutics reported its financial results for the quarter ended June 30, 2026.

Definium Therapeutics, Inc. signed an underwriting agreement for an underwritten public offering of 20,588,236 common shares at $34.00 per share, with expected gross proceeds of approximately $805 million, expected to close June 25, 2026.

Definium Therapeutics Inc. shares surged as much as 60% on Monday after positive late-stage trial data for its experimental depression drug.